Signatera Shows 100% Sensitivity in Rectal Cancer at ASTRO 2026
NTRA has more than doubled off its 52-week low of $160.59.
Summary
Natera presented four oral abstracts at ASTRO 2026 showing Signatera's strong performance in radiation oncology settings. In locally advanced rectal cancer, the test achieved 100% sensitivity and 97% specificity. In vulvovaginal cancer, ctDNA detected recurrence a median of 117 days before imaging. These data extend Signatera's validation beyond surgery into radiation oncology, a key buyer segment. The oral presentation selection adds credibility with radiation oncologists. This follows recent PMDA approval in Japan and the launch of the AFT-70 NAVIGATE Phase III trial, reinforcing the test's expanding clinical footprint.
At the time of this announcement, NTRA was trading at $429.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.4B. The 52-week trading range was $160.59 to $427.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.